About ISPOR

(1:1econd)

How was ISPOR founded? | Health Outcomes | Health Economics | ISPOR

(1:57)

Richard White talks about ISPOR 2015

(38)

AHA-ISPOR Joint Session on Real World Evidence

(9:52)

Health Economics in R | ISPOR Victoria and Tasmania Student Chapter

(57:48)

ISPOR poster: Harnessing AI in health economics

(1:18)

What's New at ISPOR? [2023]

(2:8)

ISPOR May 2022

(1:20)

A career in Market Access - Lunch \u0026 Learn with Amy Leval

(43:25)

What do you need to know about pharmacoeconomics | تقديم: منيره الرويتع رئيسة الفرع

(1:13:12)

Session 7: Advanced Methods in Economic Evaluation: Value of Perfect Information

(35:52)

Health Economics and Outcomes Research (HEOR) Panel Discussion

(57:23)

What is HEOR? | A PharmD in the Pharmaceutical Industry

(11:9)

Modelling \u0026 Markov Model

(53:)

Carpuride W702BS 7\

(33:7)

Sources Of Real-World Data

(24:54)

Checklists and Reporting Standards in Health Economics | ISPOR Victoria and Tasmania Student Chapter

(41:46)

The use of Health Economics and Outcomes Research in Healthcare

(3:55)

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Membership

(5:54)

ISPOR Efforts in Communication | Health Economics

(2:10)

Market Access 4.0: Interview with Dr. Stefan Walzer | ISPOR 2024 Barcelona

(2:33)

ISPOR Europe 2019 Conference Highlights

(2:36)

ISPOR Europe poster: Use of patient perspectives \u0026 real-world evidence in rare disease HTA

(2:28)

Virtual ISPOR Panel to Examine Next Steps in Value Assessment

(10:32)

ISPOR Glasgow Welcome

(1:13)

ISPOR Europe Poster: Health economic modelling for mental health disorders

(56)

Harnessing artificial intelligence (AI) in systematic reviews at ISPOR Europe!

(4:58)

A new role for patients in medicine: ISPOR highlights 2015

(4:37)

国际医药经济与疗效研究协会(ISPOR)展望 | ISPOR Insight | Chinese Subtitles

(2:31)